Brooks B, Rees R C
Department of Virology, University of Sheffield Medical School, UK.
Clin Exp Immunol. 1988 Nov;74(2):162-5.
The effect of recombinant human interleukin 4 (rhIL-4) on the induction in vitro of human lymphokine activated killer cell (LAK) activity was investigated. Peripheral blood mononuclear cells (PBMC) from normal healthy donors were incubated for 4 days with or without recombinant human interleukin-2 (rhIL-2) in the presence or absence of rhIL-4. LAK activity was measured against the NK-resistant colon adenocarcinoma cell line SW742, and NK mediated cytotoxicity was determined using NK sensitive K562 cells. Unlike previous reports using mouse effector cells, rhIL-4 neither induced LAK activity nor augmented the cytotoxic response induced by rhIL-2. In four out of six experiments there was a significant reduction of rhIL-2 induced LAK in the presence of rhIL-4, accompanied by a reduction of Tac antigen expression by rhIL-2 activated cells. Recombinant hIL-4 failed to influence the effector phase of the activated PBMC against SW742 or K562 targets.
研究了重组人白细胞介素4（rhIL-4）对体外诱导人淋巴因子激活的杀伤细胞（LAK）活性的影响。将来自正常健康供体的外周血单个核细胞（PBMC）在有或无rhIL-4的情况下，与重组人白细胞介素-2（rhIL-2）一起孵育4天。针对NK抗性结肠腺癌细胞系SW742测量LAK活性，并使用NK敏感的K562细胞测定NK介导的细胞毒性。与先前使用小鼠效应细胞的报道不同，rhIL-4既不诱导LAK活性，也不增强rhIL-2诱导的细胞毒性反应。在六个实验中的四个实验中，在存在rhIL-4的情况下，rhIL-2诱导的LAK显著降低，同时rhIL-2激活的细胞的Tac抗原表达也降低。重组hIL-4未能影响活化的PBMC对SW742或K562靶标的效应阶段。
